vs
Side-by-side financial comparison of ARS Pharmaceuticals, Inc. (SPRY) and TrueCar, Inc. (TRUE). Click either name above to swap in a different company.
TrueCar, Inc. is the larger business by last-quarter revenue ($43.2M vs $28.1M, roughly 1.5× ARS Pharmaceuticals, Inc.). TrueCar, Inc. runs the higher net margin — 11.6% vs -147.1%, a 158.7% gap on every dollar of revenue. On growth, TrueCar, Inc. posted the faster year-over-year revenue change (-7.2% vs -67.6%).
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
TrueCar, Inc. is an American car retailing website company headquartered in Santa Monica, California. It also maintains a sales office in Austin, Texas.
SPRY vs TRUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.1M | $43.2M |
| Net Profit | $-41.3M | $5.0M |
| Gross Margin | — | — |
| Operating Margin | -147.6% | -17.0% |
| Net Margin | -147.1% | 11.6% |
| Revenue YoY | -67.6% | -7.2% |
| Net Profit YoY | -182.8% | 185.7% |
| EPS (diluted) | $-0.41 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.1M | — | ||
| Q3 25 | $32.5M | $43.2M | ||
| Q2 25 | $15.7M | $47.0M | ||
| Q1 25 | $8.0M | $44.8M | ||
| Q4 24 | $86.6M | $46.2M | ||
| Q3 24 | $2.1M | $46.5M | ||
| Q2 24 | $500.0K | $41.8M | ||
| Q1 24 | $0 | $41.1M |
| Q4 25 | $-41.3M | — | ||
| Q3 25 | $-51.2M | $5.0M | ||
| Q2 25 | $-44.9M | $-7.6M | ||
| Q1 25 | $-33.9M | $-10.1M | ||
| Q4 24 | $49.9M | $-5.8M | ||
| Q3 24 | $-19.1M | $-5.8M | ||
| Q2 24 | $-12.5M | $-13.5M | ||
| Q1 24 | $-10.3M | $-5.8M |
| Q4 25 | -147.6% | — | ||
| Q3 25 | -163.7% | -17.0% | ||
| Q2 25 | -302.9% | -18.3% | ||
| Q1 25 | -466.3% | -25.0% | ||
| Q4 24 | 54.5% | -15.4% | ||
| Q3 24 | -1051.6% | -15.9% | ||
| Q2 24 | -3068.0% | -36.3% | ||
| Q1 24 | — | -18.2% |
| Q4 25 | -147.1% | — | ||
| Q3 25 | -157.4% | 11.6% | ||
| Q2 25 | -285.6% | -16.2% | ||
| Q1 25 | -425.7% | -22.6% | ||
| Q4 24 | 57.7% | -12.7% | ||
| Q3 24 | -925.0% | -12.5% | ||
| Q2 24 | -2503.2% | -32.3% | ||
| Q1 24 | — | -14.2% |
| Q4 25 | $-0.41 | — | ||
| Q3 25 | $-0.52 | — | ||
| Q2 25 | $-0.46 | — | ||
| Q1 25 | $-0.35 | — | ||
| Q4 24 | $0.52 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.0M | $103.2M |
| Total DebtLower is stronger | $96.4M | — |
| Stockholders' EquityBook value | $114.3M | $114.2M |
| Total Assets | $327.7M | $148.7M |
| Debt / EquityLower = less leverage | 0.84× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $245.0M | — | ||
| Q3 25 | $288.2M | $103.2M | ||
| Q2 25 | $240.1M | $92.5M | ||
| Q1 25 | $275.7M | $98.0M | ||
| Q4 24 | $314.0M | $111.8M | ||
| Q3 24 | $204.6M | $114.5M | ||
| Q2 24 | $218.7M | $128.0M | ||
| Q1 24 | $223.6M | $133.7M |
| Q4 25 | $96.4M | — | ||
| Q3 25 | $96.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $114.3M | — | ||
| Q3 25 | $147.7M | $114.2M | ||
| Q2 25 | $192.3M | $106.4M | ||
| Q1 25 | $229.0M | $111.1M | ||
| Q4 24 | $256.8M | $118.1M | ||
| Q3 24 | $201.0M | $128.0M | ||
| Q2 24 | $215.2M | $143.9M | ||
| Q1 24 | $223.9M | $156.0M |
| Q4 25 | $327.7M | — | ||
| Q3 25 | $372.8M | $148.7M | ||
| Q2 25 | $313.5M | $139.8M | ||
| Q1 25 | $327.3M | $145.0M | ||
| Q4 24 | $351.2M | $159.7M | ||
| Q3 24 | $217.6M | $167.5M | ||
| Q2 24 | $222.0M | $183.0M | ||
| Q1 24 | $227.6M | $193.5M |
| Q4 25 | 0.84× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-43.5M | $12.7M |
| Free Cash FlowOCF − Capex | — | $11.2M |
| FCF MarginFCF / Revenue | — | 25.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.5% |
| Cash ConversionOCF / Net Profit | — | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-43.5M | — | ||
| Q3 25 | $-47.0M | $12.7M | ||
| Q2 25 | $-39.6M | $-2.8M | ||
| Q1 25 | $-40.7M | $-7.9M | ||
| Q4 24 | $42.0M | $5.9M | ||
| Q3 24 | $-14.5M | $1.8M | ||
| Q2 24 | $-7.3M | $-2.0M | ||
| Q1 24 | $-6.7M | $2.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-47.2M | $11.2M | ||
| Q2 25 | $-39.6M | $-4.8M | ||
| Q1 25 | $-40.8M | $-10.6M | ||
| Q4 24 | $41.7M | $4.1M | ||
| Q3 24 | $-14.6M | $-170.0K | ||
| Q2 24 | $-7.3M | $-3.6M | ||
| Q1 24 | $-6.8M | $-511.0K |
| Q4 25 | — | — | ||
| Q3 25 | -145.4% | 25.9% | ||
| Q2 25 | -252.2% | -10.2% | ||
| Q1 25 | -512.1% | -23.6% | ||
| Q4 24 | 48.2% | 9.0% | ||
| Q3 24 | -706.3% | -0.4% | ||
| Q2 24 | -1463.4% | -8.7% | ||
| Q1 24 | — | -1.2% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.6% | 3.5% | ||
| Q2 25 | 0.3% | 4.2% | ||
| Q1 25 | 1.1% | 6.0% | ||
| Q4 24 | 0.3% | 3.7% | ||
| Q3 24 | 6.8% | 4.2% | ||
| Q2 24 | 7.6% | 3.9% | ||
| Q1 24 | — | 6.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
TRUE
Segment breakdown not available.
